CASI Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $20.7M | $28.5M | $33.9M | $43.1M | $30.2M | $15.1M |
| Cost of Revenue | $10.6M | $17.4M | $13.8M | $15.8M | $12.6M | $9.5M |
| Gross Profit | $10.1M | $11.1M | $20.1M | $27.3M | $17.6M | $5.6M |
| Gross Margin | 48.6% | 39.1% | 59.2% | 63.3% | 58.4% | 37.2% |
| Operating Expenses | ||||||
| Research & Development | $6.3M | $8.9M | $9.9M | $16.0M | — | — |
| SG&A Expense | $28.3M | $23.6M | $25.4M | $23.4M | $23.7M | $19.7M |
| Operating Income | $-45.0M | $-39.6M | $-25.1M | $-34.0M | $-41.5M | $-52.8M |
| Operating Margin | -217.3% | -138.8% | -74.0% | -78.9% | -137.6% | -348.6% |
| Interest Expense | — | — | — | $0 | $2.9K | $3.1K |
| Pretax Income | $-45.9M | $-38.1M | $-26.3M | $-37.4M | $-35.8M | $-47.5M |
| Income Tax Expense | — | $0 | $-81.0K | $2.0M | $0 | $0 |
| Net Income | $-48.1M | $-39.3M | $-27.0M | $-41.0M | $-36.7M | $-48.3M |
| Net Margin | -232.0% | -137.6% | -79.6% | -95.1% | -121.5% | -318.9% |
| EPS (Basic) | $-2.59 | $-2.56 | $-2.02 | $-3.01 | $-2.69 | $-4.37 |
| EPS (Diluted) | $-2.59 | $-2.56 | $-2.02 | $-3.01 | $-2.69 | $-4.37 |
| Shares Outstanding (Basic) | 18.5M | 15.3M | 13.4M | 13.6M | 13.6M | 11.0M |
| Shares Outstanding (Diluted) | 18.5M | 15.3M | 13.4M | 13.6M | 13.6M | 11.0M |
| Dividends Per Share | — | — | — | — | — | — |